Newsroom
Sorted by: Latest
-
Investor Alert: Robbins LLP Informs Investors of the Skechers U.S.A., Inc. Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--Skechers U.S.A., Inc. insiders face allegations that they engaged in a fraudulent scheme to buy out shareholders at an artificially depressed price....
-
Myers Industries Announces Quarterly Dividend
AKRON, Ohio--(BUSINESS WIRE)--Myers Industries Announces Quarterly Dividend...
-
Lewis Apartments Opens Independence Rental-Home Community Near Downtown Sacramento
WEST SACRAMENTO, Calif.--(BUSINESS WIRE)--Independence in West Sacramento, a new gated community of 208 townhome-style rental homes developed by Lewis Apartments, will officially open its leasing office and model homes to the public on Saturday, October 24. The leasing office and models will be open daily from 9 a.m. to 6 p.m. Located in West Sacramento’s Southport/Bridgeway Island area, Independence introduces rental homes designed for residents who want the space and privacy of a single-famil...
-
BeOne Medicines anuncia benefício sustentado de sobrevida com a combinação de TEVIMBRA e ZIIHERA no tratamento de primeira linha do câncer gastroesofágico HER2+
SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235) — empresa global de oncologia — anunciou hoje novos resultados de sobrevida provenientes da segunda análise intermediária (IA2) planejada e da análise formal final do estudo de Fase 3 HERIZON-GEA-01. Os resultados confirmam ainda mais o benefício de TEVIMBRA®(tislelizumabe) em associação com ZIIHERA® (zanidatumabe) e quimioterapia como tratamento de primeira linha para pacientes com adenocarc...
-
Samenvatting: BeOne Medicines rapporteert aanhoudend overlevingsvoordeel met combinatie van TEVIMBRA en ZIIHERA bij eerstelijnsbehandeling van HER2-positieve gastro-oesofageale kanker
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een mondiaal oncologiebedrijf, heeft vandaag nieuwe overlevingsresultaten bekendgemaakt uit de geplande tweede tussentijdse analyse (IA2) en de definitieve formele analyse van de Fase 3-studie HERIZON-GEA-01. Deze resultaten bevestigen opnieuw het voordeel van TEVIMBRA ® (tislelizumab) in combinatie met ZIIHERA® (zanidatamab) en chemotherapie als eerstelijnsbehandeling voor patiënten met HER2-posi...
-
BeOne Medicines berichtet über einen anhaltenden Überlebensvorteil durch die Kombination von TEVIMBRA und ZIIHERA bei der Erstlinienbehandlung von HER2-positivem Magen-Speiseröhren-Krebs
SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute neue Überlebensdaten aus der geplanten zweiten Zwischenanalyse (IA2) und der abschließenden formellen Analyse der Phase-3-Studie HERIZON-GEA-01-bekannt, die den Nutzen von TEVIMBRA® (Tislelizumab) in Kombination mit ZIIHERA® (Zanidatamab) und einer Chemotherapie als Erstlinienbehandlung für Patienten mit HER2-positivem, lokal fortgeschritte...
-
Riassunto: BeOne Medicines annuncia un beneficio duraturo in termini di sopravvivenza con la combinazione TEVIMBRA-ZIIHERA nel trattamento di prima linea dell'adenocarcinoma gastroesofageo HER2+
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), azienda oncologica globale, oggi ha annunciato nuovi risultati di sopravvivenza della seconda analisi ad interim (IA2) e un'analisi finale formale dello studio clinico di Fase 3 HERIZON-GEA-01, confermando ulteriormente il beneficio di TEVIMBRA® (tislelizumab) più ZIIHERA® (zanidatamab) e chemioterapia come trattamento di prima linea per i pazienti affetti da adenocarcinoma gastroesofageo (GEA) HE...
-
The Wella Company kündigt wichtige Veränderungen in der Führungsspitze an, um strategische Schwerpunkte in den Bereichen Markenaufbau, Marketing, Innovation und Lieferkette zu unterstützen
NEW YORK--(BUSINESS WIRE)--The Wella Company, das weltgrößte Unternehmen, das ausschließlich Produkte für Haare und Nägel vertreibt, gab heute strategische Veränderungen in der Führungsspitze bekannt, um die nächste Phase des Unternehmens zu unterstützen, in der auch eine neue Organisationsstruktur für den Bereich Global Brand and Marketing vorgesehen ist. The Wella Company gliedert ihren Bereich Global Brand and Marketing künftig in zwei eigenständige, sich jedoch ergänzende Teams, die jeweils...
-
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
MIAMI & SEOUL, South Korea--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit’s AI-powered pathology platform, for tumor microenvironment analysis in support of Summit’s immuno-oncology development programs with ivonescimab. The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor microenvironment featur...
-
PRIVACY ALERT: AWKO Law LLP Investigates Quest Diagnostics for Data Breach of Patient Records
SAN FRANCISCO--(BUSINESS WIRE)--AWKO Law LLP is investigating a data breach that led to unauthorized access to the sensitive information of patients of Quest Diagnostics, a New Jersey-based diagnostic testing company. Quest Diagnostics disclosed in its Securities and Exchange Commission (“SEC”) Form 8-K filing that on October 21, 2026, it identified unauthorized activity in its Quanum Lab Services Manager, a platform where certain clients can place test orders and receive or look up their resul...